HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy.

AbstractBACKGROUND & AIMS:
Development of liver metastases is a frequent complication in patients with colorectal cancer (CRC), even after successful resection of the primary tumor. As such, post-operative adjuvant therapies that aim to eliminate residual disease after surgery may improve patient outcome.
METHODS:
We used a colon carcinoma liver metastases model, in which CC531s colon carcinoma cells are injected into the portal circulation by a surgical procedure. As injected tumor cells are arrested in the liver, this model is suitable for investigating the interaction of tumor cells with the liver microenvironment. By administering tumor specific monoclonal antibodies (mAb) directly post-operatively, we were able to determine the effect of antibody therapy on eradication of arrested tumor cells and subsequent liver metastases outgrowth.
RESULTS:
We showed that post-operative treatment with tumor specific monoclonal antibodies (mAb) prevents liver metastases outgrowth. Antibody-dependent phagocytosis (ADPh) was the main mechanism involved, as enhanced uptake of tumor cells by innate mononuclear phagocytes in the liver was observed after mAb therapy. Furthermore, Kupffer cells (KC) were identified as the most prominent effector cells, as depletion of KC abolished therapeutic efficacy. This was partly compensated by monocytes when animals were treated with a high mAb dose, but monocytes were unable to phagocytose tumor cells when rats were treated with low mAb doses.
CONCLUSIONS:
The finding that KC and monocytes can eliminate tumor cells through ADPh has important and promising clinical implications for designing new adjuvant therapies for patients undergoing CRC resection.
AuthorsGerben J van der Bij, Marijn Bögels, Marielle A Otten, Steven J Oosterling, Peter J Kuppen, Sybren Meijer, Robert H J Beelen, Marjolein van Egmond
JournalJournal of hepatology (J Hepatol) Vol. 53 Issue 4 Pg. 677-85 (Oct 2010) ISSN: 1600-0641 [Electronic] Netherlands
PMID20619916 (Publication Type: Journal Article)
CopyrightCopyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Colorectal Neoplasms (drug therapy, pathology, surgery)
  • Combined Modality Therapy
  • Humans
  • Leukocytes, Mononuclear
  • Liver Neoplasms (drug therapy, prevention & control, secondary, surgery)
  • Liver Neoplasms, Experimental
  • Mice
  • Phagocytes
  • Phagocytosis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: